Limits...
Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression.

Andersen AH, Smith CD, Slevin JT, Kryscio RJ, Martin CA, Schmitt FA, Blonder LX - Parkinsons Dis (2015)

Bottom Line: Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status.DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs.Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY 40536, USA; Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, KY 40536, USA.

ABSTRACT
Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

No MeSH data available.


Related in: MedlinePlus

Dopaminergic medication by depression interaction in the ventromedial prefrontal cortex (VMPFC) in PD patients; data points depict the average value across emotion categories from the 4th column of Table 2. Error bars represent the standard error of the mean.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4697088&req=5

fig2: Dopaminergic medication by depression interaction in the ventromedial prefrontal cortex (VMPFC) in PD patients; data points depict the average value across emotion categories from the 4th column of Table 2. Error bars represent the standard error of the mean.

Mentions: An ANOVA for a crossover design was used with depression as the between subjects factor (present or absent) and dopaminergic medication status (on or off), emotion category (angry, happy, or sad), and hemisphere (left or right) as within subjects factors. Age and education served as covariates in the analysis, although neither variable was found to be correlated with the fMRI activation/deactivation response and therefore would not affect the result. This analysis revealed a significant three-way interaction between depression, dopaminergic medication status, and emotion category (F(2,48) = 4.76; P = 0.013). The three-way interaction may be driven by a significant interaction between depression and dopaminergic medication status for happy faces (F(1,24) = 6.72; P = 0.016). There was no effect of hemisphere. Table 2 lists the least squares marginal means averaged across hemispheres for this VMPFC region; the averages across emotion categories for the depression by medication design are displayed in Figure 2.


Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression.

Andersen AH, Smith CD, Slevin JT, Kryscio RJ, Martin CA, Schmitt FA, Blonder LX - Parkinsons Dis (2015)

Dopaminergic medication by depression interaction in the ventromedial prefrontal cortex (VMPFC) in PD patients; data points depict the average value across emotion categories from the 4th column of Table 2. Error bars represent the standard error of the mean.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4697088&req=5

fig2: Dopaminergic medication by depression interaction in the ventromedial prefrontal cortex (VMPFC) in PD patients; data points depict the average value across emotion categories from the 4th column of Table 2. Error bars represent the standard error of the mean.
Mentions: An ANOVA for a crossover design was used with depression as the between subjects factor (present or absent) and dopaminergic medication status (on or off), emotion category (angry, happy, or sad), and hemisphere (left or right) as within subjects factors. Age and education served as covariates in the analysis, although neither variable was found to be correlated with the fMRI activation/deactivation response and therefore would not affect the result. This analysis revealed a significant three-way interaction between depression, dopaminergic medication status, and emotion category (F(2,48) = 4.76; P = 0.013). The three-way interaction may be driven by a significant interaction between depression and dopaminergic medication status for happy faces (F(1,24) = 6.72; P = 0.016). There was no effect of hemisphere. Table 2 lists the least squares marginal means averaged across hemispheres for this VMPFC region; the averages across emotion categories for the depression by medication design are displayed in Figure 2.

Bottom Line: Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status.DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs.Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY 40536, USA; Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, KY 40536, USA.

ABSTRACT
Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

No MeSH data available.


Related in: MedlinePlus